Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID-tunniste: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns (2012)
- Cancer Research
(O2 Muu julkaisu ) - High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML (2012)
- Blood
(O2 Muu julkaisu ) - Identification of Personalized Therapeutic Strategies and Associated Biomarkers in Adult Acute Myeloid Leukemia Using a Functional Drug Sensitivity and Resistance Testing Platform (2012)
- European Journal of Cancer
(O2 Muu julkaisu ) - Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo (2012)
- Clinical Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Mining high-throughput screens for cancer drug targets - lessons from yeast chemical-genomic profiling and synthetic lethality (2012)
- Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Obatoclax, Saliphenylhalamide, and Gemcitabine Inhibit Influenza A Virus Infection (2012)
- Journal of Biological Chemistry
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Optimized detection of transcription factor binding sites in ChIP-seq experiments (2012)
- Nucleic Acids Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Optimizing Detection of Transcription Factor-Binding Sites in ChIP-seq Experiments (2012)
- Nucleic Acids Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Pravastatin-induced improvement in coronary reactivity and circulating ATP and ADP levels in young adults with type 1 diabetes (2012)
- Frontiers in Physiology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance (2012)
- Cancer Research
(O2 Muu julkaisu )



